In another study with less heavily pre-treated patients with advanced cervical cancer (n = 19), an overall response rate (ORR) of 26% was observed after nivolumab (anti-PD-1) treatment, including a complete response in a patient lacking tumoral PD-L1 expression (27). The gene discussed is CD274; the disease is cervical carcinoma.